The study compared the new dual-drug combination doravirine/islatravir (100/0.75 mg) with the standard triple-drug regimen bictegravir/emtricitabine/tenofovir-alafenamide as initial treatment for HIV-1 in adult patients[1][2]. 597 patients participated in the trial and were randomly divided into both treatment groups[2]. After 48 weeks, viral suppression (HIV-1 RNA <50 copies/mL) was achieved in 88.9% of patients in the doravirine/islatravir group and 88.3% in the triple regimen group, indicating that the new combination was equally effective[2][3]. The safety profile of the two regimens was comparable, with serious adverse events occurring in 9.7% versus 11.7% of patients[3]. However, the study was terminated earlier than planned due to observed CD4 and lymphocyte declines in other studies with islatravir[2]. Despite the positive results, development of this dose of doravirine/islatravir was halted precisely because of these safety concerns[2].